Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 25.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | set forth by specific reference in such a filing. Item 5.02Departure of Directors or Certain Officers; Election of Direc |
| 30.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
Stammdaten
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Unternehmen & Branche
| Name | Aprea Therapeutics, Inc. |
|---|---|
| Ticker | APRE |
| CIK | 0001781983 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,3 Mio. USD |
| Beta | 1,57 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -12,599,569 | -1.93 | 15,933,401 | 12,441,682 | |
| 2025-09-30 | 10-Q | -2,972,410 | -0.47 | 14,321,316 | 10,912,848 | |
| 2025-06-30 | 10-Q | -3,238,870 | -0.53 | 17,309,710 | 13,414,681 | |
| 2025-03-31 | 10-Q | -3,932,659 | -0.66 | 20,222,083 | 15,549,922 | |
| 2024-12-31 | 10-K | -12,958,711 | -2.35 | 23,979,493 | 19,307,455 | |
| 2024-09-30 | 10-Q | -3,783,769 | -0.64 | 26,893,969 | 21,947,018 | |
| 2024-06-30 | 10-Q | -3,470,052 | -0.58 | 29,964,587 | 25,559,295 | |
| 2024-03-31 | 10-Q | -2,810,091 | -0.67 | 33,200,006 | 28,923,867 | |
| 2023-12-31 | 10-K | -14,286,756 | -3.95 | 22,650,174 | 16,953,506 | |
| 2023-09-30 | 10-Q | -3,204,515 | -0.86 | 25,766,423 | 20,289,298 | |
| 2023-06-30 | 10-Q | -3,259,097 | -0.87 | 28,680,668 | 23,418,784 | |
| 2023-03-31 | 10-Q | -4,379,890 | -1.34 | 32,020,429 | 26,481,978 | |
| 2022-12-31 | 10-K | -112,662,027 | -67.99 | 30,155,827 | 25,643,678 | |
| 2022-09-30 | 10-Q | -4,024,718 | -2.32 | 33,621,904 | 26,625,228 | |
| 2022-06-30 | 10-Q | -98,258,474 | -86.72 | 40,683,836 | -35,777,829 | |
| 2022-03-31 | 10-Q | -7,936,693 | -7.25 | 50,337,009 | 43,588,826 | |
| 2021-12-31 | 10-K | -37,127,303 | -34.88 | 56,823,463 | 49,506,964 | |
| 2021-09-30 | 10-Q | -9,452,351 | -0.45 | 62,484,860 | 53,415,271 | |
| 2021-06-30 | 10-Q | -10,251,013 | -0.48 | 71,549,730 | 60,951,669 | |
| 2021-03-31 | 10-Q | -9,668,755 | -0.46 | 80,394,665 | 69,146,164 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | Gilad Oren | Director, Officer, President/CEO | Open Market Purchase | 28,100 | 0.89 | 25,009.00 | +164,2% | |
| 2026-01-30 | Hamill John P. | Officer, SrVP/CFO/Prin Fin & Acct Ofcr | Open Market Purchase | 5,700 | 0.89 | 5,073.00 | +33,3% | |
| 2025-12-10 | Duey Marc | Director | Open Market Purchase | 21,459 | 1.17 | 24,999.74 | +164,2% | |
| 2025-12-10 | Hamill John P. | Officer, SrVP/CFO/Prin Fin & Acct Ofcr | Open Market Purchase | 5,000 | 1.17 | 5,825.00 | +38,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.